Clinical manifestations, which are insidious in onset, include memory loss and cognitive decline (Scheltens et al., 2016)
Semaglutide 24 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial
"We arrived early and were greeted with friendly and knowledgeable professionalism
BioAges primary focus is in developing medications that boost a persons healthspan, or the number of healthy years a person lives
Hartmann N, Mason FE, Braun I, Pabel S, Voigt N, Schotola H, Fischer TH, Dobrev D, Danner BC, Renner A, Gummert J, Belardinelli L, Frey N, Maier LS, Hasenfuss G, Sossalla S (2016) The combined effects of ranolazine and dronedarone on human atrial and ventricular electrophysiology